to the barrier imposed by the outer stratum corneum layer of the skin. Accordingly, considerable research efforts are focused on drug permeation, and various enhancing methods have been tried: iontophoresis and electroporation 14, 15 , phonophoresis 16, 17 , chemical methods and absorption enhancers 18, 19 . Recently, strategies using micro/ nanoparticles have been developed and investigated. Nanoparticles can be engineered to carry drug payloads, image contrast agents, or gene therapeutics for diagnosing and treating disease, with cancer being a primary focus, and research into nanomedicines has increased enormously during the past years 20 28 . The size of a particle influences its functionality in terms of uptake, residence in circulation, adherence, degradation, as well as clearance 29 33 .
The fate of particles inside the body has been reported as follows 34 : 2 mm, trapped inside liver cells; 300 -400 nm, captured by macrophages and excreted; 200 nm, filtered in the spleen; 100 nm, escape from blood vessels through the endothelial lining. Thus, size governs the movement of nanoparticles inside tissues. We also reported that a dermal application using these nanoparticles enhanced drug permeability through the skin 35 . It is expected that drug systems using nanoparticles may provide an alternative strategy for increasing drug permeation 36 39 , and it is possible that a topical drug delivery system using nanoparticles may lead to an expansion of their usage as therapy for RA patients. Here, we have designed new topical formulations containing IMC solid nanoparticles, and investigated their pharmacokinetics. In addition, we demonstrate the preventive effects of these IMC nanoparticle formulations on inflammation in adjuvant-induced arthritis AA rats.
EXPERIMENTAL 2.1 Animals and reagents
Male Wistar rats, aged 7 weeks, and Dark Agouti DA rats, aged 6 to 13 weeks, were housed under standard conditions 12 h/d fluorescent light 07:00-19:00 , 25 room temperature , and allowed free access to a commercial diet CE-2, Clea Japan Inc., Tokyo, Japan and water. 2-Hydroxypropyl-β-cyclodextrin HPβCD, average molar substitution, 0.6; average MW, 1380 was purchased from Nihon Shokuhin Kako Co., Ltd. Tokyo, Japan . Low-substituted methylcellulose MC, METOLOSE SM-4, average viscosity, 4 Pa s at 20 was provided by Shin-Etsu Chemical Co., Ltd. Tokyo, Japan . Carboxypolymethylene Carbopol ® 934 was obtained from Serva Heidelberg, Germany . Conventional IMC solid, IMC microparticles, 17.1 11.6 mm, means S.D. was purchased from Wako Pure Chemical Industries, Ltd. Osaka, Japan . All other chemicals used were of the highest purity commercially available. The dispersity of the nanoparticles in the ointment base was confirmed as follows : 1 IMC micro and IMC nano gel ointments were divided into 10 parts, and the IMC concentration in each part was measured by HPLC IMC micro , 0.99 0.11; IMC nano , 1.05 0.06, , means S.E., n 10 . Figure  1 shows the particle size of the 1 IMC micro and IMC nano gel ointments. The particle size was measured using a nanoparticle size analyzer SALD-7100 Shimadzu Corp., Kyoto, Japan; refractive index 1.60-0.10i . The IMC micro and IMC nano gel ointments were stable for one month after preparation mean particle size: IMC micro , 17.8 12.6; IMC nano , 0.191 0.105, mm, means S.D. , and no decrease in IMC concentration in the IMC micro or IMC nano gel ointments was observed during the one month.
Release of IMC from IMC gel ointments
An experiment was carried out using 100 and 450 nm pore size membrane filters MF TM -MEMBRANE FILRER, Merck Millipore, Tokyo, Japan and a Franz diffusion cell 35, 43 .
The donor side of the membrane filter was soaked in buffer 0.85 NaCl-10 mM phosphate buffer, pH 7.4 for 12 h at 4 to equilibrate the membrane. Then 0.3 g IMC gel ointment was spread uniformly over the membrane, which was then mounted in the Franz diffusion cell reservoir volume 12.2 ml, 1.6 cm i.d. O-ring flange , and occluded with aluminium foil. The diffusion cells were thermoregulated in a water bath at 37 for 24 h. One hundred microliter aliquots of sample solution were withdrawn from the reservoir chamber at the indicated time intervals and replaced with the same volume of buffer. Ten microliters of filtrate was added to 100 ml methanol containing 0.1 mg propyl phydroxybenzoate internal standard , and the mixture was filtered through a Chromatodisk 4A pore size 0.45 mm, Kurabo Industries Ltd., Osaka, Japan . The filtered solution 10 ml was injected into an Inertsil ® ODS-3 3 mm, column size: 2.1 mm 50 mm column GL Science Co., Inc., Tokyo, Japan on a Shimadzu LC-20AT system equipped with a column oven CTO-20A Shimadzu Corp., Kyoto, Japan . The mobile phase consisted of acetonitrile/50 mM acetic acid 40/60, v/v at a flow rate of 0.25 mL/min; the column temperature was 35 , and the wavelength for detection was 254 nm.
2.4
In vitro skin penetration of IMC micro and IMC nano gel ointments The in vitro skin penetration experiment was carried out using the Franz diffusion cell 35, 43 . On the day before the experiment, the hair on the abdominal area of 7 weekold Wistar rats was carefully removed with an electric clipper and electric razor. The following day, pieces 3 3 cm area of full-thickness abdominal skin were excised from the rats, and the adherent fat and other visceral debris were removed from the undersurface. The dermal side of the full-thickness skin was soaked in buffer 0.85 NaCl-10 mM phosphate buffer, pH 7.4 for 12 h at 4 to equilibrate the skin. Then 0.3 g IMC gel ointment was uniformly spread over the stratum corneum of the skin, which was then mounted in a Franz diffusion cell reservoir volume 12.2 ml, 1.6 cm i.d. O-ring flange , and occluded with aluminium foil. The diffusion cells were thermoregulated in a water bath at 37 for 30 h. The IMC concentrations in the samples were determined by the HPLC method described above. The data obtained were analyzed using the following formula Eqs. 1-3 35, 44 :
where J c is the IMC penetration rate, K m is the skin/preparation partition coefficient, D is the diffusion constant within the skin, t lag is the lag time, δ is thickness of the skin 0.071 cm, average for 5 rats , Q t is the total amount of IMC appearing in the reservoir solution at time t, and A is the effective area of skin 2 cm 2 ; J c and t lag were estimated by fitting each penetration profile to Eq. 3. The penetration coefficient through the skin, K p , is given by J c /C IMC . A nonlinear least-squares computer program MULTI was em- Gel ointments were dispersed in water, and the particle sizes were determined using a nanoparticle size analyzer SALD-7100 (refractive index 1.60-0.10i). Mean particle size: IMC micro gel ointment, 17.5 ± 12.0; IMC nano gel ointment, 0.186 ± 0.101, mm, means ± S.D.
ployed for the calculation 45 .
2.5
In vivo percutaneous absorption of IMC micro and IMC nano gel ointments On the day before the experiment, the hair on the abdominal area of 7 week-old Wistar rats was carefully removed with an electric clipper and electric razor, and a cannula filled with 30 mg/ml heparin silicone tubing; I.D., 0.5 mm, O.D., 1.0 mm was inserted into the right jugular vein under isoflurane anesthesia. 0.3 g of IMC gel ointment was fixed on the shaved abdominal skin with an adhesive and immediately occluded with adhesive tape. At 24 h after the start of the experiment, the skin surface to which the gel ointment was applied was washed with saline, and the IMC gel ointments were reapplied. Venous blood 200 ml was collected at 0-96 h after the application of IMC gel ointment from the jugular vein through the cannula. The blood was centrifuged at 3,000 rpm for 20 min at 4 , and the plasma obtained was stored at 80 until IMC analysis. The IMC concentrations in the samples were determined by the HPLC method described above. The IMC concentration in the plasma after a single injection of 0.3 ml of IMC solution 200 mg/kg into the femoral vein was analyzed according to Eq. 4 35 :
Eq. 4
where C IMC is IMC concentration in the plasma, C 0 is the initial concentration of IMC in the plasma 2.68 0.13 mg/ ml , k e is the elimination rate constant for IMC from the plasma. The k e and distribution volume V d data obtained from 5 experiments were 0.05 0.07 h 1 and 52.1 1.98 ml/kg, respectively. The absorption of IMC after a single administration of IMC gel ointment was calculated as the apparent absorption rate constant k a , h 1 according to Eq. 5 35 : where t is the interval after IMC administration 24 h , N is the frequency of IMC administration. A nonlinear leastsquares computer program MULTI was employed for these calculation Eqs. 4-6 . The area under the IMC concentration-time curve AUC 0-24h was analyzed according to the following equation Eq. 7 :
Briefly, AUC 0-24h was determined according to the trapezoidal rule up to 24 h, which was the time of the final IMC concentration measurement.
2.6 Accumulation of IMC micro and IMC nano gel ointments in skin tissue On the day before the experiment, the hair on the abdominal area of 7 week-old Wistar rats was carefully removed with an electric clipper and electric razor. The following day, 0.3 g of IMC gel ointment was fixed on the shaved abdominal skin with an adhesive and immediately occluded with adhesive tape. At 24 h after the start of the experiment, the skin surface to which the gel ointment was applied was washed with saline, and the IMC gel ointments were reapplied. The gel ointment on the skin surface was wiped off with an Elleair Prowipe Soft Micro Wiper S220
Prowipe, DAIO PAPER CORPORATION, Tokyo, Japan soaked in saline, and pieces 2 cm 2 of abdominal skin to which the IMC gel ointments were applied were excised at 0-24 h after application. The adherent fat and other visceral debris were removed from the undersurface, and the skin samples obtained were stored at -80 until IMC analysis. The frozen skin was homogenized in methanol using a Physcotron homogenizer MICROTEC CO., LTD., Chiba, Japan . The homogenates were centrifuged at 15,000 rpm for 20 min at 4 , and the supernatants were used for the measurement of IMC. The IMC concentrations in the samples were determined by the HPLC method described above.
Application of IMC gel ointments to AA rats
Arthritis was induced by the injection of 50 ml of adjuvant, a suspension of 10 mg/ml heat-killed Mycobacterium butyricum Difco, Detroit, MI in Bayol F oil, into the plantar region of the right hind foot and tail of DA rats. The control group received 50 ml of Bayol F oil alone. The rats were hooded to prevent them from licking, and 0.3 g of IMC gel ointment was applied to the right foot daily 9:00 . When reapplying the gel ointment, the old gel ointment on the skin surface was first wiped off with saline on a Prowipe. The application of IMC gel ointments was started after adjuvant injection. In this study, inflammation during the development of AA was assessed by measuring paw volume paw edema , a parameter of inflammation, by plethysmometry. In this paper, the inflammatory scores are represented as AUC the area under the paw volume-time curve, AUC 0-42d . The values of AUC 0-42d were calculated according to the following equation Eq. 8 :
Eq. 8
where V and t are the paw volume and the number of days
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after adjuvant injection, respectively.
Statistical analysis
All values are represented as mean standard error of the mean S.E. . Unpaired Student s or Aspin-Welch s t-tests were used to determine statistical difference, and multiple groups were evaluated by one-way analysis of variance ANOVA followed by Dunnett s multiple comparison. P values less than 0.05 were considered significant.
RESULTS AND DISCUSSION

Percutaneous Penetration of IMC Released from
IMC micro and IMC nano Gel Ointments First, we prepared IMC nanoparticles. Additives are very important in the preparation of high quality nanomedicines since they affect the environment around the surface of the particles. In a previous study, we found that the addition of HPβCD and MC was suitable for the preparation of nanoparticles using mill methods 35, 40 42 . HPβCD is a cyclic oligosaccharide with a hydrophilic outer surface and a lipophilic cavity in its center. It is capable of forming inclusion complexes with many lipophilic drugs by taking up the drug molecule, or part of it, into the lipophilic cavity 46, 47 .
Moreover, HPβCD enhances the stability of drug dispersions containing nanoparticles by attaching to the surface of the nanoparticles 35, 40 42 . MC is a water-soluble substance with a high degree of purity, uniformity and transparency. MC solutions are neutral, odorless, and tasteless, and are also stable over a wide pH range. We have reported that MC is needed to prepare drug nanoparticles by the bead mill method 35, 40 42 . Therefore, the IMC nanoparticles were prepared using additives HPβCD and MC and Bead Smash 12, which resulted in the preparation of high quality IMC nanoparticles particle size, 173 91 nm, means S.D. . The data indicate that the milled IMC nanoparticles are homogeneous with a narrow particle size distribution. Clinically, ointments, creams and gels are used in formulations for dermal application, and gels are particularly used pharmaceutically as lubricants as well as carriers for many drugs to provide a local effect and percutaneous absorption 48, 49 . Therefore, a gel ointment containing IMC nanoparticles was prepared using Carbopol 934, which has excellent thickening, emulsifying and gelling properties, allowing the uniform incorporation of the IMC nanoparticles Fig. 1 . The IMC micro and IMC nano gel ointments were stable for one month after preparation mean particle size: IMC micro , 17.8 12.6; IMC nano , 0.191 0.105, mm, means S.D. , with no decrease in IMC concentration in either ointment observed during the one month. These results show that the procedures developed in this study are suitable for the preparation of gel ointments containing IMC nanoparticles.
Next, the drug release and skin penetration of IMC micro and IMC nano gel ointments was demonstrated. Figure 2 shows the penetration profiles of IMC through a membrane filter after the application of IMC micro and IMC nano gel ointments. Although the IMC release from the IMC nano gel ointment was similar to that from the IMC micro gel ointment in experiments using 100 nm pore size membranes, the IMC penetration profile of the IMC nano gel ointment through a 450 nm pore size membrane was significantly higher than that of the IMC micro gel ointment, and the release from the IMC micro gel ointment was 38.9 of that from the IMC nano gel ointment 24 h after the application of 1 IMC gel ointment. This result suggests that the IMC emitted from the IMC nano gel ointment remains in the state of IMC nanoparticles. Figure 3 shows the penetration profiles of IMC through rat skin after the application of IMC micro and IMC nano gel ointments, and Fig. 4 shows the absorption profiles of IMC through rat skin following the applications of IMC micro and IMC nano gel ointments. Table 1 and 2 summarize the pharmacokinetic parameters calculated from the in vitro skin penetration data Table 1 and the in vivo percutaneous absorption data Table 2 . In the in vitro rat skin penetration experiments, the amounts of IMC that penetrated the skin increased linearly in the case of both IMC gel ointments up to 30 h after the application of the gel ointment Fig. 3 . Therefore, we used data collected in the 0 -30 h range to calculate the pharmacokinetic parameters Table  1 . The amount of penetrated IMC, the penetration rate J c , penetration coefficient through the skin K p and skin/ preparation partition coefficient K m values of the IMC nano gel ointment were all significantly higher than those of the IMC micro gel ointment. The diffusion constant within the skin D and lag time t lag for the IMC micro and IMC nano gel ointments showed no significant difference. However, the absorption profiles of IMC through the skin following the applications of IMC micro and IMC nano gel ointments were similar Fig. 4A and Table 2 , and the IMC plasma concentration following the repetitive administration of the IMC micro or IMC nano gel ointments reached a plateau at 48-96 h with a value of 1.4 -3.0 mg/ml concentration at steady state, C ss , Fig. 4 . On the other hand, the IMC concentrations in the skin tissue of rats receiving the IMC nano gel ointment were significantly higher than those of rats receiving the IMC micro gel ointment Fig. 5 . We show that the supply of IMC from the IMC nano gel ointment was higher than that from IMC micro gel ointment in this study Figs. 2 and 3 . Therefore, the greater amount of IMC from the IMC nano gel ointment may be related to the IMC concentrations in the skin tissue, and the IMC in skin may show only a limited shift to the blood.
These results show that the characteristics of the IMC micro and IMC nano gel ointments in skin differ. In addition, we demonstrated the plasma concentration and accumulation in the skin following the application of a commercially available IMC gel ointment IDOMETHINE KOWA gel 1 . The plasma concentration following the repetitive administration of IMC nano gel ointment was lower than that following the commercially available ointment C ss , 10.3 -22.9 mg/ The data represent the means ± S.E. of 6 rats.
ml , and the IMC concentrations in the skin tissue of rats receiving the IMC nano gel ointment were significantly higher than those of rats receiving the commercially available ointment 1.26 0.22 mmol/cm 2 , means S.E. n 6 rats .
These results suggest that the effects for local therapy are greater following the application of the IMC nano gel ointment than the IMC micro gel ointment or the commercially available IMC gel ointment.
Therapeutic Effects of IMC micro and IMC nano Gel Ointments on Paw Edema in AA Rats
In studies to develop new topical formulations containing IMC solid nanoparticles for treating RA, the selection of the experimental animal is very important. The AA rat is an animal model in which arthritis is induced by the injection of an adjuvant. Inflammatory pain during the development of AA is assessed by measuring paw edema 50, 51 . Paw edema in AA rats is known to involve two inflammatory processes, primary and secondary inflammation. Primary inflammation starts from the day following the injection of adjuvant into the right hind foot. Secondary inflammation is observed from 7 days after adjuvant injection, and reaches a maximum in both feet 14 days after adjuvant injection into the right and/or left hind foot 4, 52 . It is noteworthy that changes in the biological characteristics of AA rats correspond to those that occur in human RA 4, 50 52 . Therefore, AA rats provide a useful model for use in studies to evaluate transdermal therapeutic systems in RA. Figure 6 and Table 3 show the preventive effects of IMC micro and IMC nano gel ointments on paw edema in AA rats. Paw edema in the right hind foot injected with adjuvant appeared on the day following injection, and reached a maximum after 14 days Fig. 6A . On the other hand, paw edema of the left hind foot, which was not injected with adjuvant, was not observed during the first 7 days after adjuvant injection, but clearly increased from 10 days, and reached a maximum at 14 days Fig. 6B . The application of commercially available ointment was significantly prevented the increase in paw edema of the right and left hind feet of AA right hind feet 29.8 0.85, left hind feet 24.8 0.68, ml day, means S.E. n 6 rats . This result showed that the increase in plasma IMC concentration caused the suppression of paw edema in both of right and left hind feet. Although, paw edema of the right hind feet of AA rats to which the IMC micro gel ointment was applied tended to be less than, no significant difference was found in comparison with AA rats treated with gel ointment containing no IMC control gel ointment . In contrast to the results in AA rats treated with the IMC micro gel ointment, paw edema of the right hind feet of AA rats to which the IMC nano gel ointment was less in the days following adjuvant injection, and the AUC 0-42d values were significantly lower than those of AA rats treated with control gel ointment or the IMC micro gel ointment Table 3 . On the other hand, the paw edema of the left hind feet of AA rats to which the IMC micro or IMC nano gel ointment was applied did not differ significantly from that of rats receiving the control gel ointment. These data suggest that the achievement of relatively high local IMC concentrations in the case of the IMC nano gel ointment resulted in effective therapy. Further studies are needed to elucidate the precise mechanism for the skin penetration of gel ointments containing IMC nanoparticles. In addition, it is important to clarify a suitable formulation and particle size for a dermal application for RA using IMC particles. Therefore, we are now investigating the therapeutic effects of a topical drug delivery system using IMC particles of various sizes on inflammation and pharmacokinetics in AA rats.
CONCLUSIONS
IMC, 1-4-chlorobenzoyl -5-methoxy-2-methylindol-3-yl acetic acid, molecular weight 357.8, pKa 4.5, has been used as therapy for RA patients. However, gastrointestinal lesions are the most common side effect in patients taking IMC, and RA patients taking IMC are more susceptible to IMC-induced gastrointestinal lesions in comparison with other patients 4 8, 11 . Therefore, the development of IMC formulations that do not cause gastrointestinal lesions is highly anticipated. In this study, we have developed a new topical drug delivery system that includes IMC nanoparticles using Bead Smash 12 and additives including HPβCD, MC and Carbopol 934. The accumulation of IMC from the gel ointment in skin tissue and the therapeutic effect on inflammation for the IMC nano gel ointment were significantly greater than those for the IMC micro gel ointment; however, the plasma IMC concentrations were similar between the IMC micro and IMC nano gel ointments. Our findings suggest that a dermal application using nanoparticles may enable a medication to be applied without leading to high systemic levels, providing efficient and effective therapy that spares or nanoparticles (closed triangles) was applied to the right foot once a day (9:00). The data are presented as means ± S.E. of 6 independent rats. *p < 0.05 vs. IMC micro gel ointment for each category. 
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patients from unwanted side effects. A formulation of a topical drug delivery system using IMC nanoparticles may provide a delivery option for the clinical treatment of RA.
